CY1114877T1 - Παραγωγα φαινυλ πυραζολιου - Google Patents
Παραγωγα φαινυλ πυραζολιουInfo
- Publication number
- CY1114877T1 CY1114877T1 CY20141100018T CY141100018T CY1114877T1 CY 1114877 T1 CY1114877 T1 CY 1114877T1 CY 20141100018 T CY20141100018 T CY 20141100018T CY 141100018 T CY141100018 T CY 141100018T CY 1114877 T1 CY1114877 T1 CY 1114877T1
- Authority
- CY
- Cyprus
- Prior art keywords
- narcolepsy
- pyrazoli
- finish products
- hyperlipidaemia
- hyperlipidemia
- Prior art date
Links
- 201000003631 narcolepsy Diseases 0.000 abstract 4
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 150000008048 phenylpyrazoles Chemical class 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 208000020685 sleep-wake disease Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007294040 | 2007-11-13 | ||
| JP2008153736 | 2008-06-12 | ||
| EP08849725.0A EP2221298B1 (en) | 2007-11-13 | 2008-11-13 | Phenylpyrazole derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1114877T1 true CY1114877T1 (el) | 2016-12-14 |
Family
ID=40638800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20141100018T CY1114877T1 (el) | 2007-11-13 | 2014-01-09 | Παραγωγα φαινυλ πυραζολιου |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US7888354B2 (enExample) |
| EP (1) | EP2221298B1 (enExample) |
| JP (2) | JP4543344B2 (enExample) |
| KR (1) | KR101571176B1 (enExample) |
| CN (1) | CN101855211B (enExample) |
| AU (1) | AU2008321823B2 (enExample) |
| BR (1) | BRPI0820432B8 (enExample) |
| CA (1) | CA2705502C (enExample) |
| CY (1) | CY1114877T1 (enExample) |
| DK (1) | DK2221298T3 (enExample) |
| ES (1) | ES2436146T3 (enExample) |
| HR (1) | HRP20131060T1 (enExample) |
| IL (2) | IL205509A (enExample) |
| MX (1) | MX2010005225A (enExample) |
| MY (1) | MY173546A (enExample) |
| NZ (1) | NZ585661A (enExample) |
| PH (1) | PH12012501917A1 (enExample) |
| PL (1) | PL2221298T3 (enExample) |
| PT (1) | PT2221298E (enExample) |
| RS (1) | RS53125B (enExample) |
| RU (1) | RU2480456C2 (enExample) |
| SI (1) | SI2221298T1 (enExample) |
| WO (1) | WO2009063953A1 (enExample) |
| ZA (1) | ZA201003111B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100113776A1 (en) * | 2006-12-14 | 2010-05-06 | Taisho Pharmaceutical Co.,Ltd. | Pyrazole derivative |
| CN101855211B (zh) * | 2007-11-13 | 2013-06-12 | 大正制药株式会社 | 苯基吡唑衍生物 |
| JP5740838B2 (ja) * | 2009-05-12 | 2015-07-01 | 大正製薬株式会社 | フェニルピラゾール誘導体 |
| BR112014013461A2 (pt) * | 2011-12-08 | 2017-06-13 | Taisho Pharmaceutical Co Ltd | derivado de fenilpirrol |
| US20150045553A1 (en) * | 2011-12-27 | 2015-02-12 | Taisho Pharmaceutical Co., Ltd | Phenyltriazole derivative |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| EP2928474B1 (en) | 2012-12-07 | 2018-11-14 | ChemoCentryx, Inc. | Diazole lactams |
| JP6263553B2 (ja) * | 2013-01-17 | 2018-01-17 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｃｎｓ疾患の処置のためのオキシトシン受容体アゴニスト |
| SG11201808626WA (en) | 2016-04-07 | 2018-10-30 | Chemocentryx Inc | Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL104311A (en) * | 1992-02-05 | 1997-07-13 | Fujisawa Pharmaceutical Co | Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
| ATE354568T1 (de) | 2000-08-08 | 2007-03-15 | Ortho Mcneil Pharm Inc | Nicht-imidazol aryloxypiperidine als h3 rezeptor liganden |
| US6316475B1 (en) * | 2000-11-17 | 2001-11-13 | Abbott Laboratories | Aminoalkoxybiphenylcarboxamides as histamine-3 receptor ligands and their therapeutic applications |
| EP1370546A2 (en) * | 2001-03-16 | 2003-12-17 | Abbott Laboratories | Novel amines as histamine-3 receptor ligands and their therapeutic applications |
| AU2004257025B9 (en) | 2003-06-27 | 2010-05-27 | Msd K.K. | Heteroaryloxy nitrogenous saturated heterocyclic derivative |
| US7423147B2 (en) | 2004-03-31 | 2008-09-09 | Janssen Pharmaceutical, N.V. | Pyridine compounds as histamine H3 modulators |
| GB0408083D0 (en) | 2004-04-08 | 2004-05-12 | Glaxo Group Ltd | Novel compounds |
| FR2870846B1 (fr) * | 2004-05-25 | 2006-08-04 | Sanofi Synthelabo | Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique |
| SE0401971D0 (sv) | 2004-08-02 | 2004-08-02 | Astrazeneca Ab | Piperidne derivatives |
| CN101006082B (zh) | 2004-08-23 | 2010-09-29 | 伊莱利利公司 | 组胺h3受体药剂、制备方法和治疗用途 |
| MX2007004465A (es) | 2004-10-19 | 2007-05-07 | Hoffmann La Roche | Derivados de quinolina. |
| WO2006046131A1 (en) | 2004-10-29 | 2006-05-04 | Pfizer Products Inc. | Tetralin histamine-3 receptor antagonists |
| CA2588867A1 (en) | 2004-12-01 | 2006-06-08 | Banyu Pharmaceutical Co., Ltd. | Substituted pyridone derivative |
| US20090306052A1 (en) | 2004-12-07 | 2009-12-10 | Glaxo Group Limited | Indenyl derivatives and use thereof for the treatment of neurological disorders |
| CA2602336A1 (en) * | 2005-03-31 | 2006-10-05 | Ucb Pharma S.A. | Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses |
| AU2006232871B9 (en) | 2005-04-01 | 2011-11-24 | Eli Lilly And Company | Histamine H3 receptor agents, preparation and therapeutic uses |
| DE102005033448A1 (de) * | 2005-07-18 | 2007-01-25 | Josef Gail | Druckgas-Zylinderläufermotor |
| GB0514812D0 (en) * | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| GB0514811D0 (en) * | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| ATE525072T1 (de) | 2006-02-09 | 2011-10-15 | Athersys Inc | Pyrazole zur behandlung von adipositas und anderen zns-erkrankungen |
| US20100113776A1 (en) | 2006-12-14 | 2010-05-06 | Taisho Pharmaceutical Co.,Ltd. | Pyrazole derivative |
| CN101711232A (zh) * | 2007-04-12 | 2010-05-19 | Dsm精细化学奥地利Nfg两合公司 | 邻-氯甲基苯基乙醛酸酯、(e)-2-(2-氯甲基苯基)-2-烷氧亚胺基乙酸酯的改进制备方法以及用于这些制备方法的新型中间体 |
| CN101855211B (zh) * | 2007-11-13 | 2013-06-12 | 大正制药株式会社 | 苯基吡唑衍生物 |
-
2008
- 2008-11-13 CN CN200880115707XA patent/CN101855211B/zh not_active Expired - Fee Related
- 2008-11-13 AU AU2008321823A patent/AU2008321823B2/en not_active Ceased
- 2008-11-13 SI SI200831096T patent/SI2221298T1/sl unknown
- 2008-11-13 HR HRP20131060AT patent/HRP20131060T1/hr unknown
- 2008-11-13 KR KR1020107009179A patent/KR101571176B1/ko not_active Expired - Fee Related
- 2008-11-13 MX MX2010005225A patent/MX2010005225A/es active IP Right Grant
- 2008-11-13 JP JP2009541174A patent/JP4543344B2/ja not_active Expired - Fee Related
- 2008-11-13 RU RU2010123924/04A patent/RU2480456C2/ru active
- 2008-11-13 PT PT88497250T patent/PT2221298E/pt unknown
- 2008-11-13 US US12/741,754 patent/US7888354B2/en active Active
- 2008-11-13 NZ NZ585661A patent/NZ585661A/en not_active IP Right Cessation
- 2008-11-13 PL PL08849725T patent/PL2221298T3/pl unknown
- 2008-11-13 ES ES08849725T patent/ES2436146T3/es active Active
- 2008-11-13 MY MYPI2010002187A patent/MY173546A/en unknown
- 2008-11-13 RS RS20130586A patent/RS53125B/sr unknown
- 2008-11-13 DK DK08849725.0T patent/DK2221298T3/da active
- 2008-11-13 CA CA2705502A patent/CA2705502C/en active Active
- 2008-11-13 WO PCT/JP2008/070712 patent/WO2009063953A1/ja not_active Ceased
- 2008-11-13 BR BRPI0820432A patent/BRPI0820432B8/pt not_active IP Right Cessation
- 2008-11-13 PH PH1/2012/501917A patent/PH12012501917A1/en unknown
- 2008-11-13 EP EP08849725.0A patent/EP2221298B1/en active Active
-
2010
- 2010-02-05 JP JP2010024303A patent/JP5375639B2/ja not_active Expired - Fee Related
- 2010-05-03 IL IL205509A patent/IL205509A/en active IP Right Grant
- 2010-05-04 ZA ZA2010/03111A patent/ZA201003111B/en unknown
- 2010-11-22 US US12/951,964 patent/US8183387B2/en not_active Expired - Fee Related
- 2010-11-22 US US12/951,978 patent/US8193176B2/en not_active Expired - Fee Related
-
2014
- 2014-01-09 CY CY20141100018T patent/CY1114877T1/el unknown
- 2014-12-04 IL IL236083A patent/IL236083A/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1114877T1 (el) | Παραγωγα φαινυλ πυραζολιου | |
| LTC2137143I2 (lt) | Pleuromutilino dariniai, skirti mikrobų sukeltų ligų gydymui | |
| MX2011008336A (es) | Derivados de dihidroquinolinona. | |
| MX2013001614A (es) | Compuestos heterociclico. | |
| WO2012137982A3 (en) | Sulfonamide derivative and use thereof | |
| GEP20115176B (en) | Prodrug of cinnamide compound | |
| MX2010006204A (es) | Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina. | |
| GEP20115172B (en) | Bicyclic cinnamide compound | |
| IL194789A0 (en) | Terphenyl derivatives for treatment of alzheimer's disease | |
| CY1112418T1 (el) | Παραγωγα σουλφονυλοπυραζολινο-1-καρβοξαμιδινης ως 5-ητ6 ανταγωνιστες | |
| DK1670903T3 (da) | Behandling af neurodegenerative sygdomme | |
| MX2009012376A (es) | Derivados de pirimidona sustituidos con heteroarilamida para el tratamiento de enfermedades neurodegenerativas. | |
| PT1778837E (pt) | Tratamento de doenças neurodegenerativas por utilização de inibidores de scd4 | |
| DE602006014305D1 (de) | Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors | |
| PH12014501293A1 (en) | Phenylpyrrole derivative | |
| MX2018015397A (es) | Co-cristales de benzoato de sodio y sus usos. | |
| DE602006010738D1 (de) | Pyrroloä2,3-cüpyridinderivate | |
| FR2921656B1 (fr) | Procede de synthese d'arylamines | |
| BRPI0414107A (pt) | produtos intermediários para a preparação de hìbridos de oxazolidinon-quinolona | |
| WO2006065600A3 (en) | N-biaryl and n-arylheteroaryl piperazine derivatives as modulators of the 5ht2c receptor useful for the treatment of disorders related thereto | |
| ATE518833T1 (de) | Aminoarylsulfonamidverbindungen und ihre verwendung als 5-ht6-liganden | |
| MX2010004311A (es) | Productos intermedios de moduladores de gamma-secretasa. | |
| WO2007017511A3 (de) | Verbindungen zur behandlung der alzheimer erkrankung | |
| AU2008339005A8 (en) | 3,4-substituted pyrrolidine beta-secretase inhibitors for the treatment of Alzheimer's disease | |
| DE602006017849D1 (de) | 5,6-disubstituierte oxadiazolopyrazine und thiadiazolopyrazine als liganden des cxc-chemokinrezeptors |